The following represents disclosure information provided by authors of this abstract. The Genitourinary Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Serum IGF-1 levels in men with advanced prostate cancer treated with the ERĪ± agonist, GTx-758.
Evan Y. Yu
Consultant or Advisory Role - GTx
Research Funding - GTx
Marc Gittelman
Research Funding - GTx
Thomas E. Keane
Consultant or Advisory Role - GTx
Research Funding - GTx
Ronald Tutrone
Research Funding - GTx
Laurence Belkoff
Research Funding - GTx
Robert Given
Research Funding - GTx
Joel Bass
Research Funding - GTx
Franklin Chu
Consultant or Advisory Role - GTx
Research Funding - GTx
Mike Gambla
Research Funding - GTx
Franklin Gaylis
Research Funding - GTx
James Bailen
Consultant or Advisory Role - GTx
Research Funding - GTx
Robert H. Getzenberg
Employment or Leadership Position - GTx; GTx
Stock Ownership - GTx; GTx
Christopher Coss
Employment or Leadership Position - GTx
Stock Ownership - GTx
Michael L. Hancock
Employment or Leadership Position - GTx
Stock Ownership - GTx
James T. Dalton
Employment or Leadership Position - GTx
Stock Ownership - GTx
Mitchell S. Steiner
Employment or Leadership Position - GTx
Stock Ownership - GTx